Moleculin (MBRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HAMPTON, N.J., Sept. 30, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Celldex Therapeutics, Inc. (CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and scientific conferences. CDX-1140: The abstract (Abstract ID: P827) entitled, “Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers” will be presented in a poster presentation by Rachel Sanborn, MD, Co-director of the Thoracic Oncology Program and Leader of the Phase 1 Trials Program at Providence Cancer Institute and a lead investigator in this study, on Friday, November 8, 2019 from 8:00 am to 8:00 pm ET. Michael Yellin, MD, Vice President of Clinical Science at Celldex will also present a talk entitled CD40: A Target for Systemic Immune Modulation at the Workshop on Intratumoral Immunomodulation on Thursday, November 7, 2019 at 3:00 pm ET.
Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
HAMPTON, N.J., May 06, 2020 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020. “Despite.
Celldex Therapeutics, Inc. (CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells.
Is (CLDX) Outperforming Other Medical Stocks This Year?
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is (CLDX) Outperforming Other Medical Stocks This Year?
Celldex Therapeutics, Inc. (CLDX) announced today that the Company will receive a $1.7 million payment related to an existing 2013 agreement with Rockefeller University under which Celldex performed manufacturing and development services for Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including two clinical-stage candidates 3BNC117 and 10-1074. This portfolio was licensed by Gilead Sciences in January of 2020 from Rockefeller University and pursuant to Celldex’s agreement with Rockefeller, Celldex will receive an upfront payment of $1.7 million as a result of this transaction and is eligible to receive additional milestone payments as these products progress through clinical development plus royalties on potential future sales.
Celldex Therapeutics, Inc. (CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with voice over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020, which this year will be held digitally June 6-8, 2020. The study will be presented by Dr. Marcus Maurer, Professor of Dermatology and Allergy and Director of Research at the Department of Dermatology and Allergy at the Allergie-Centrum-Charité of the Charité - Universitätsmedizin in Berlin. Dr. Maurer is also head of the Specialty Clinics for Urticaria, Mastocytosis, Pruritus and Angioedema and the Dermatological Allergology Lab.
UroGen (URGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
HAMPTON, N.J., Nov. 12, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019..
Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.
Celldex Therapeutics, Inc. (CLDX) presented data from the Company’s ongoing CD40 agonist program today at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting. CD40, expressed on dendritic cells and other antigen presenting cells, is an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses.
HAMPTON, N.J., March 26, 2020 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31,.
Celldex (CLDX) delivered earnings and revenue surprises of 10.71% and -56.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics, Inc. (CLDX) presented data from the Company’s preclinical pipeline this weekend. A review of the CDX-0159 early development program was presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting on November 9, 2019 in the Distinguished Industry Oral Abstract Session. Preclinical data supporting the continued development of the Company’s CDX-527 bispecific candidate were also presented at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting (SITC 2019), including both a poster presentation on November 9, 2019 and a talk during the preconference program session “Novel Multi-Targeted Therapeutic Platforms” on Wednesday, November 6, 2019.